# The Study of Quantitative Serial Trends in Lipids With ApolpoproteinA-I Stimulation

> **NCT01423188** · PHASE2 · COMPLETED · sponsor: **Resverlogix Corp** · enrollment: 176 (actual)

## Conditions studied

- Coronary Artery Disease
- Dyslipidemia

## Interventions

- **DRUG:** RVX000222
- **DRUG:** Placebo RVX000222

## Key facts

- **NCT ID:** NCT01423188
- **Lead sponsor:** Resverlogix Corp
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2012-06
- **Final completion:** 2012-08
- **Target enrollment:** 176 (ACTUAL)
- **Last updated:** 2012-09-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01423188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01423188, "The Study of Quantitative Serial Trends in Lipids With ApolpoproteinA-I Stimulation". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01423188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*